Item 1.01 Entry into a Material Definitive Agreement.

As previously disclosed, Ocugen, Inc. (the "Company"), is party to a Co-Development, Supply and Commercialization Agreement, as amended (the "Agreement") with Bharat Biotech International Limited ("Bharat"), pursuant to which the Company obtained an exclusive right and license under certain of Bharat's intellectual property rights, with the right to grant sublicenses, to develop, manufacture and commercialize COVAXIN™, an advanced-stage whole-virion inactivated vaccine candidate/product for the prevention of COVID-19 in the United States of America and Canada (the "Ocugen Territory").

On April 15, 2022, the Company and Bharat entered into that certain Second Amendment to the Co-Development, Supply and Commercialization Agreement (the "Amendment"), pursuant to which the parties agreed to expand the Ocugen Territory to include Mexico (the "Amended Ocugen Territory"). Under the terms of the Agreement, as amended by the Amendment, the parties will share any profits generated from the commercialization of COVAXIN™ in the Amended Ocugen Territory, with the Company retaining 45% of such profits and Bharat receiving the balance of such profits.

The foregoing summary of the material terms of the Amendment is qualified in its entirety by the terms of the Amendment, a copy which will be filed as an exhibit in a subsequent periodic report to be filed under the Securities Exchange Act of 1934, as amended.

© Edgar Online, source Glimpses